FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379511019> ?p ?o ?g. }

• W4379511019 abstract "<h3>Background</h3> A 3^rd COVID-19 vaccination is currently recommended for patients under immunosuppression. However, a fast decline of antibodies against the SARS-CoV-2 receptor-binding domain (RBD) of the spike protein has been observed. <h3>Objectives</h3> It remains unclear whether immunosuppressive therapy affects kinetics of humoral and cellular immune responses. <h3>Methods</h3> 50 patients under immunosuppression and 42 healthy controls (HCs) received a 3^rd dose of an mRNA-based vaccine and were monitored over a 12-weeks period. Humoral immune response was assessed 4 and 12 weeks after 3^rd dose. Antibodies were quantified using the Elecsys Anti-SARS-CoV-2 Spike immunoassay against the receptor-binding domain (RBD) of the spike protein. SARS-CoV-2-specific T cell responses were quantified by IFN-γ ELISpot assays. Adverse events, including SARS-CoV-2 infections, were monitored over a 12-week period. <h3>Results</h3> At week 12, reduced anti-RBD antibody levels were observed in IMID patients as compared to HCs (median antibody level 5345 BAU/ml [1781 – 10208] versus 9650 BAU/ml [6633 - 16050], p < 0.001). Reduction in relative antibody levels was significantly higher in IMID patients as compared to HCs at week 12 (p < 0.001). Lowest anti-RBD antibody levels were detected in IMID patients who received biological diseases modifying anti-rheumatic drugs (DMARDs) or a combination therapy with conventional synthetic and biological DMARDs. Number of SARS-CoV-2-specific T cells against wildtype and Omicron variants remained stable over 12 weeks in IMID patients. No serious adverse events were reported. <h3>Conclusion</h3> Due to a fast decline in anti-RBD antibodies in IMID patients an early 4^th vaccination should be considered in this vulnerable group of patients. <h3>REFERENCES:</h3> NIL. <h3>Acknowledgements:</h3> NIL. <h3>Disclosure of Interests</h3> Daniel Mrak Consultant of: AstraZeneca, Felix Kartnig: None declared, Daniela Sieghart: None declared, Elisabeth Simader Speakers bureau: Lilly, Helga Radner Speakers bureau: Gilead, Merck Sharp and Pfizer, Peter Mandl: None declared, Lisa Göschl: None declared, Philipp Hofer: None declared, Thomas Deimel: None declared, Irina Gessl: None declared, Renate Kain Speakers bureau: Otsuka, Consultant of: AstraZeneca, Takeda Pharma, MEDahead and Janssen Cilag, Stefan Winkler: None declared, Josef S. Smolen Consultant of: AbbVie, Amgen, AstraZeneca, Astro, Bristol-Myers Squibb, Celltrion, Gilead-Galapagos, Janssen, Lilly, Pfizer, R-Pharma, Samsung, Sanofi, Chugai, Merck Sharp & Dohme, Novartis-Sandoz Roche, Samsung and UCB, Grant/research support from: Abbvie, AstraZeneca, Lilly, Novartis, and Roche, Thomas Perkmann: None declared, Helmuth Haslacher Grant/research support from: Glock Health, BlueSky Immunotherapies and Neutrolis, Daniel Aletaha Speakers bureau: Abbvie, Amgen, Galapagos, Lilly, Janssen, Merck, Novartis, Pfizer, Sandoz, and Sanofi, Consultant of: Abbvie, Amgen, Galapagos, Lilly, Janssen, Merck, Novartis, Pfizer, Sandoz, and Sanofi, Grant/research support from: Abbvie, Amgen, Galapagos, Lilly, Janssen, Merck, Novartis, Pfizer, Sandoz, and Sanofi, Leonhard Heinz: None declared, Michael Bonelli Consultant of: EliLilly." @default.
• W4379511019 created "2023-06-07" @default.
• W4379511019 creator A5002614470 @default.
• W4379511019 creator A5011017158 @default.
• W4379511019 creator A5011740108 @default.
• W4379511019 creator A5031092545 @default.
• W4379511019 creator A5043829152 @default.
• W4379511019 creator A5047517354 @default.
• W4379511019 creator A5049066597 @default.
• W4379511019 creator A5049257873 @default.
• W4379511019 creator A5053649177 @default.
• W4379511019 creator A5054550346 @default.
• W4379511019 creator A5058529400 @default.
• W4379511019 creator A5060460712 @default.
• W4379511019 creator A5061411814 @default.
• W4379511019 creator A5066602987 @default.
• W4379511019 creator A5073438436 @default.
• W4379511019 creator A5081837070 @default.
• W4379511019 creator A5084504971 @default.
• W4379511019 creator A5085246771 @default.
• W4379511019 date "2023-05-30" @default.
• W4379511019 modified "2023-10-06" @default.
• W4379511019 title "POS0559 ACCELERATED WANING OF HUMORAL IMMUNE RESPONSE TO A THIRD COVID-19 VACCINATION IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES" @default.
• W4379511019 doi "https://doi.org/10.1136/annrheumdis-2023-eular.6402" @default.
• W4379511019 hasPublicationYear "2023" @default.
• W4379511019 type Work @default.
• W4379511019 citedByCount "0" @default.
• W4379511019 crossrefType "proceedings-article" @default.
• W4379511019 hasAuthorship W4379511019A5002614470 @default.
• W4379511019 hasAuthorship W4379511019A5011017158 @default.
• W4379511019 hasAuthorship W4379511019A5011740108 @default.
• W4379511019 hasAuthorship W4379511019A5031092545 @default.
• W4379511019 hasAuthorship W4379511019A5043829152 @default.
• W4379511019 hasAuthorship W4379511019A5047517354 @default.
• W4379511019 hasAuthorship W4379511019A5049066597 @default.
• W4379511019 hasAuthorship W4379511019A5049257873 @default.
• W4379511019 hasAuthorship W4379511019A5053649177 @default.
• W4379511019 hasAuthorship W4379511019A5054550346 @default.
• W4379511019 hasAuthorship W4379511019A5058529400 @default.
• W4379511019 hasAuthorship W4379511019A5060460712 @default.
• W4379511019 hasAuthorship W4379511019A5061411814 @default.
• W4379511019 hasAuthorship W4379511019A5066602987 @default.
• W4379511019 hasAuthorship W4379511019A5073438436 @default.
• W4379511019 hasAuthorship W4379511019A5081837070 @default.
• W4379511019 hasAuthorship W4379511019A5084504971 @default.
• W4379511019 hasAuthorship W4379511019A5085246771 @default.
• W4379511019 hasBestOaLocation W43795110191 @default.
• W4379511019 hasConcept C126322002 @default.
• W4379511019 hasConcept C159654299 @default.
• W4379511019 hasConcept C203014093 @default.
• W4379511019 hasConcept C22070199 @default.
• W4379511019 hasConcept C2776090121 @default.
• W4379511019 hasConcept C2776548049 @default.
• W4379511019 hasConcept C2779053233 @default.
• W4379511019 hasConcept C2780252810 @default.
• W4379511019 hasConcept C71924100 @default.
• W4379511019 hasConcept C8891405 @default.
• W4379511019 hasConceptScore W4379511019C126322002 @default.
• W4379511019 hasConceptScore W4379511019C159654299 @default.
• W4379511019 hasConceptScore W4379511019C203014093 @default.
• W4379511019 hasConceptScore W4379511019C22070199 @default.
• W4379511019 hasConceptScore W4379511019C2776090121 @default.
• W4379511019 hasConceptScore W4379511019C2776548049 @default.
• W4379511019 hasConceptScore W4379511019C2779053233 @default.
• W4379511019 hasConceptScore W4379511019C2780252810 @default.
• W4379511019 hasConceptScore W4379511019C71924100 @default.
• W4379511019 hasConceptScore W4379511019C8891405 @default.
• W4379511019 hasLocation W43795110191 @default.
• W4379511019 hasOpenAccess W4379511019 @default.
• W4379511019 hasPrimaryLocation W43795110191 @default.
• W4379511019 hasRelatedWork W1997822423 @default.
• W4379511019 hasRelatedWork W2008184737 @default.
• W4379511019 hasRelatedWork W2019378992 @default.
• W4379511019 hasRelatedWork W209514875 @default.
• W4379511019 hasRelatedWork W2100609764 @default.
• W4379511019 hasRelatedWork W2134569739 @default.
• W4379511019 hasRelatedWork W2414222088 @default.
• W4379511019 hasRelatedWork W2416010474 @default.
• W4379511019 hasRelatedWork W3037401902 @default.
• W4379511019 hasRelatedWork W3214021846 @default.
• W4379511019 isParatext "false" @default.
• W4379511019 isRetracted "false" @default.
• W4379511019 workType "article" @default.